Mutant KRAS as a prognostic biomarker after hepatectomy for rectal cancer metastases: does the primary disease site matter?

ConclusionsWhile the left-sided colonic disease is frequently grouped with rectal disease, our analysis suggests that there exist fundamental biologic differences that drive disparate outcomes. Although there was a trend toward significance of KRAS mutations for patients with primary rectal cancers, it failed to achieve statistical significance.

Source: Journal of Hepato-Biliary-Pancreatic Surgery - October 6, 2021 Category: Surgery Authors: Neda Amini, Nikolaos Andreatos, Georgios Antonios Margonis, Stefan Buettner, Jaeyun Wang, Boris Galjart, Doris Wagner, Kazunari Sasaki, Anastasios Angelou, Jinger Sun, Carsten Kamphues, Andrea Beer, Daisuke Morioka, Inger Marie L øes, Efsta Tags: ORIGINAL ARTICLE Source Type: research